Century Therapeutics opened higher at $1.75, compared with its previous close of $1.74. In the last trading session, the stock traded between $1.60 and $1.75. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Century Therapeutics is now worth
$ 7.76
Resulting in a loss of
$ 92.24 (92.24%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.12 (-6.67%)
Day High
$1.75
Day Low
$1.60
Day Open
$1.75
Prev Close
$1.74
Volume
5,46,124
1W Return
-2.46%
1M Return
12.39%
3M Return
-21.36%
6M Return
-29.08%
1Y Return
188.30%
Fundamentals
Market Cap ($ Mn)
294
PE Ratio
-
PB Ratio
1.57
PEG Ratio
-
ROE
-5.06%
ROCE
-6.96%
EPS (TTM)
$-0.19
Investment Returns
1 Week
-2.46%
1 Month
12.39%
3 Months
-21.36%
6 Months
-29.08%
9 Months
-9.27%
Financials
Quarterly
All values in $ Mn
109.2
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
2Oct
Century Therapeutics presents CNTY-813 data at EASD 2026
Century Therapeutics presented nonclinical data for CNTY-813 at EASD 2026. IND submission for CNTY-813 remains on track for Q4 2026. Study showed sustained glycemic control in diabetic mice for over 11 months. Manufacturing process demonstrated consistency across five clinical-scale batches. Initial clinical data anticipated in second half of 2027.
1mo ago
10Sep
Century Therapeutics appoints Joseph Truitt to board of directors
Century Therapeutics appoints Joseph Truitt to its Board of Directors. Truitt is CEO of iECURE, Inc. and Chairman of Larimar Therapeutics. He previously led BioSpecifics Technologies and Achillion Pharmaceuticals. Appointment aligns with IND submission plans for CNTY-813 in Q4 2026. CNTY-308 cell therapy program expected to enter clinic in 2026.
2mo ago
9Jun
CNTY-813 shows durable glucose control and immune evasion in preclinical studies
Century Therapeutics announced new preclinical data for CNTY-813, its iPSC-derived islet replacement therapy, demonstrating durable glucose control and immune evasion without immunosuppression. The data, presented at the American Diabetes Association 86th Scientific Sessions, highlight the therapy's potential as a functional cure for type 1 diabetes, with IND submission targeted for the fourth quarter of 2026.
